drugset
drugset / Trial / NCT01296568

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

NCT01296568 ↗

Phase 1 Completed 3 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors. After a minimum 7-day washout period following the carbon-14-labeled LY2603618 (\[\^14C\]LY2603618) dose, patients will be allowed to continue to receive continued access to LY2603618 in combination with pemetrexed or gemcitabine as outpatients.

Timeline

Start
2011-02
Primary completion
2011-12
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject RABUSERTIB Small molecule 230 mg Intravenous
Subject RABUSERTIB Small molecule 250 mg Intravenous
Subject RABUSERTIB Small molecule 275 mg Intravenous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

No indication recorded.